Tagawa, Scott T.

Publications

Sort by

Co-Author Network

selected publications

Quality of life in the year after new diagnosis with advanced prostate cancer for Black and White individuals living in the US. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2023 Academic Article GET IT
Times cited: 17
Antibody-drug conjugates for urothelial carcinoma. Urologic oncology. 2023 Review GET IT
Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023 Academic Article GET IT
SNMMI Consensus Statement on Patient Selection and Appropriate Use of ¹⁷⁷Lu-PSMA-617 Radionuclide Therapy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2023 Academic Article GET IT
Health-related quality of life and pain outcomes with [¹⁷⁷Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. The Lancet. Oncology. 2023 Academic Article GET IT
Times cited: 1
Complex implementation factors demonstrated when evaluating cost-effectiveness and monitoring racial disparities associated with [¹⁸F]DCFPyL PET/CT in prostate cancer men. Scientific reports. 2023 Academic Article GET IT
Management of Lymph Node-positive Penile Cancer: A Systematic Review. European urology. 2023 Review GET IT
α-Labeling of J591, an Antibody Targeting Prostate-Specific Membrane Antigen: The Technique and Considerations from the First Dedicated Production Lab at an Academic Institution in the United States. Journal of nuclear medicine technology. 2023 Academic Article GET IT
Response to RL-225Ac in prostate cancer: Effect of prior treatment with RL-177Lu: A systematic review of the literature. The Prostate. 2023 Review GET IT
Times cited: 1
Reply to Timothée Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.022. European urology. 2023 Editorial Article GET IT
European Association of Urology-American Society of Clinical Oncology Collaborative Guideline on Penile Cancer: 2023 Update. European urology. 2023 Review GET IT
Times cited: 3
Management of Fibroblast Growth Factor Inhibitor Treatment-emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma. European urology open science. 2023 Academic Article GET IT
Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2023 Academic Article GET IT
Times cited: 1
Cyclotron vs generator-produced 68Ga PSMA: a single-institution, prospective clinical trial. Translational oncology. 2022 Academic Article GET IT
Times cited: 10
Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan. OncoTargets and therapy. 2022 Review GET IT
Ischemic stroke with cancer: Hematologic and embolic biomarkers and clinical outcomes. Journal of thrombosis and haemostasis : JTH. 2022 Academic Article GET IT
Times cited: 3
Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay. NAR cancer. 2022 Academic Article GET IT
Times cited: 2
The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer. JNCI cancer spectrum. 2022 Academic Article GET IT
Times cited: 4
What Is the Most Effective Management of the Primary Tumor in Men with Invasive Penile Cancer: A Systematic Review of the Available Treatment Options and Their Outcomes. European urology open science. 2022 Review GET IT
Times cited: 2
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. Nature communications. 2022 Academic Article GET IT
Times cited: 2
The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy. Molecular oncology. 2022 Academic Article GET IT
Times cited: 4
Correction to: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. Prostate cancer and prostatic diseases. 2022 Article GET IT
Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. Prostate cancer and prostatic diseases. 2022 Article GET IT
Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma. British journal of cancer. 2022 Academic Article GET IT
Times cited: 6
Use of Biosimilar Medications in Oncology. JCO oncology practice. 2022 Review GET IT
Times cited: 7
Adherence to Guideline-Recommended Cancer Screening in Stroke Survivors: A Nationwide Analysis. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. 2022 Academic Article GET IT
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. The Lancet. Oncology. 2022 Academic Article GET IT
Times cited: 39
Pilot study of the diagnostic utility of ⁸⁹ Zr-df-IAB2M and ⁶⁸ Ga-PSMA-11 PET imaging and multiparametric MRI in localized prostate cancer. The Prostate. 2022 Academic Article GET IT
Times cited: 6
Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. European urology open science. 2021 Academic Article GET IT
Times cited: 377
Treatment patterns and survival in metastatic castration-sensitive prostate cancer in the US Veterans Health Administration. Cancer medicine. 2021 Academic Article GET IT
Times cited: 8
Prostate-Specific Membrane Antigen Positron Emission Tomography and the New Algorithm for Patients With Prostate Cancer Prior to Prostatectomy. JAMA oncology. 2021 Comment GET IT
Times cited: 2
A case report of a patient with plasmacytoid urothelial cancer with significant response to HER2-targeting therapy and enfortumab vedotin. 2021 GET IT
Reply to T. Powles et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Letter GET IT
PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. Prostate cancer and prostatic diseases. 2021 Review GET IT
Times cited: 9
A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. NPJ precision oncology. 2021 Academic Article GET IT
Times cited: 307
Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing. The oncologist. 2021 Academic Article GET IT
Times cited: 6
A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of urothelial cancer. Urologic oncology. 2021 Review GET IT
A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of penile cancer. Urologic oncology. 2021 Review GET IT
Times cited: 1
Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage. Communications biology. 2021 Academic Article GET IT
Times cited: 3
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. The New England journal of medicine. 2021 Academic Article GET IT
Times cited: 592
Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. Nature communications. 2021 Academic Article GET IT
Times cited: 21
Re: Early Results of Unilateral Prostatic Artery Embolization as a Focal Therapy in Patients with Prostate Cancer under Active Surveillance: Cancer Prostate Embolization, a Pilot Study. Journal of vascular and interventional radiology : JVIR. 2021 Letter GET IT
Mechanisms of Ischemic Stroke in Patients with Cancer: A Prospective Study. Annals of neurology. 2021 Academic Article GET IT
Times cited: 20
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Academic Article GET IT
Times cited: 18
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Academic Article GET IT
Times cited: 141
Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer. European journal of cancer (Oxford, England : 1990). 2021 Academic Article GET IT
Times cited: 16
A Phase II, Nonrandomized Open Trial Assessing Pain Efficacy with Radium-223 in Symptomatic Metastatic Castration-resistant Prostate Cancer. Clinical genitourinary cancer. 2021 Academic Article GET IT
Times cited: 2
A 25-year review of advances in testicular cancer: Perspectives on evaluation, treatment, and future directions/challenges. Urologic oncology. 2021 Review GET IT
Times cited: 2
Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapies for Prostate Cancer. Current oncology reports. 2021 Review GET IT
Times cited: 5
Emerging Prostate-specific Membrane Antigen-based Therapeutics: Small Molecules, Antibodies, and Beyond. European urology focus. 2021 Review GET IT
Times cited: 8
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. Prostate cancer and prostatic diseases. 2021 Academic Article GET IT
Times cited: 18
Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer. Frontiers in oncology. 2021 Academic Article GET IT
Times cited: 198
PSMA-targeted therapy in prostate cancer. Clinical advances in hematology & oncology : H&O. 2021 Article GET IT
A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals. European journal of nuclear medicine and molecular imaging. 2021 Academic Article GET IT
Times cited: 22
Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer. The Prostate. 2021 Academic Article GET IT
Times cited: 7
Common germline-somatic variant interactions in advanced urothelial cancer. Nature communications. 2020 Academic Article GET IT
Times cited: 13
Folate hydrolase-1 (FOLH1) is a novel target for antibody-based brachytherapy in Merkel cell carcinoma. Skin health and disease. 2020 Academic Article GET IT
Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer. JCO precision oncology. 2020 Academic Article GET IT
Times cited: 40
Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical Data. The Journal of urology. 2020 Academic Article GET IT
Times cited: 3
Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. The Prostate. 2020 Review GET IT
Times cited: 15
Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (¹⁷⁷Lu-J591) for metastatic castration-resistant prostate cancer. Urologic oncology. 2020 Academic Article GET IT
Times cited: 20
Subcutaneous in situ gel delivered leuprolide acetate's consistent and prolonged drug delivery maintains effective testosterone suppression independent of age and weight in men with prostate cancer. BJUI compass. 2020 Academic Article GET IT
CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. JCO precision oncology. 2020 Academic Article GET IT
Times cited: 94
Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. The Journal of clinical investigation. 2020 Academic Article GET IT
Times cited: 88
An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer. Expert opinion on pharmacotherapy. 2020 Review GET IT
Times cited: 8
CD8⁺ T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens. Molecular therapy : the journal of the American Society of Gene Therapy. 2020 Academic Article GET IT
Times cited: 9
SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy. Molecular cancer therapeutics. 2020 Academic Article GET IT
Times cited: 32
Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (¹⁷⁷ Lu-J591) for Metastatic Castration-Resistant Prostate Cancer. The oncologist. 2020 Academic Article GET IT
Times cited: 24
Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Academic Article GET IT
Times cited: 38
NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma. Investigational new drugs. 2020 Academic Article GET IT
Times cited: 8
PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study. The Prostate. 2019 Academic Article GET IT
Times cited: 36
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. The Lancet. Oncology. 2019 Academic Article GET IT
Times cited: 55
Clinical Significance of AR-V567es in Prostate Cancer-Response. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Letter GET IT
Times cited: 1
Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. JCO precision oncology. 2019 Academic Article GET IT
Times cited: 36
Clinical features of neuroendocrine prostate cancer. European journal of cancer (Oxford, England : 1990). 2019 Academic Article GET IT
Times cited: 138
Cancer-Related Ischemic Stroke Has a Distinct Blood mRNA Expression Profile. Stroke. 2019 Academic Article GET IT
Times cited: 9
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. The New England journal of medicine. 2019 Academic Article GET IT
Times cited: 677
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nature communications. 2019 Academic Article GET IT
Times cited: 102
Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (¹⁷⁷ Lu-J591) for metastatic castration-resistant prostate cancer. Cancer. 2019 Academic Article GET IT
Times cited: 73
Exceptional Response to Pembrolizumab in a Patient With Castration-Resistant Prostate Cancer With Pancytopenia From Myelophthisis. 2019 GET IT
Times cited: 3
Androgen receptor nuclear localization correlates with AR-V7 mRNA expression in circulating tumor cells (CTCs) from metastatic castration resistance prostate cancer patients. Physical biology. 2019 Academic Article GET IT
Times cited: 10
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Science translational medicine. 2019 Academic Article GET IT
Times cited: 83
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 218
Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer. 2019 GET IT
Times cited: 4
Arterial thromboembolic events preceding the diagnosis of cancer in older persons. Blood. 2018 Academic Article GET IT
Times cited: 109
Expression of AR-V7 and ARv^567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 74
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 130
Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 113
Antibody-Drug Conjugates in Bladder Cancer. Bladder cancer (Amsterdam, Netherlands). 2018 Review GET IT
Times cited: 5
Patient derived organoids to model rare prostate cancer phenotypes. Nature communications. 2018 Academic Article GET IT
Times cited: 203
Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group. The Prostate. 2018 Review GET IT
Times cited: 30
Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. European urology. 2018 Academic Article GET IT
Times cited: 90
Bone biopsy protocol for advanced prostate cancer in the era of precision medicine. Cancer. 2017 Academic Article GET IT
Times cited: 33
A critical review on ramucirumab in the treatment of advanced urothelial cancer. Future oncology (London, England). 2017 Review GET IT
Times cited: 5
Metastasectomy in older adults with urothelial carcinoma: Population-based analysis of use and outcomes. Urologic oncology. 2017 Academic Article GET IT
Times cited: 12
Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Academic Article GET IT
Times cited: 55
Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models. JCO precision oncology. 2017 Academic Article GET IT
Times cited: 584
Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer. Cancer treatment reviews. 2017 Review GET IT
Times cited: 131
Trimodality therapy in variant urothelial carcinoma: choose wisely. Translational andrology and urology. 2017 Editorial Article GET IT
Times cited: 196
Immune-checkpoint blockade in cisplatin-ineligible patients with urothelial cancer. Lancet (London, England). 2016 Comment GET IT
Times cited: 1
Antibody therapeutics for treating prostate cancer: where are we now and what comes next?. Expert opinion on biological therapy. 2016 Review GET IT
Times cited: 5
Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nature genetics. 2016 Academic Article GET IT
Times cited: 201
Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer. World journal of urology. 2016 Review GET IT
Times cited: 9
OC-14 - Baseline D-dimer levels are predictive of recurrent venous thromboembolism (VTE) at 6 months in cancer patients with VTE treated with tinzaparin. Thrombosis research. 2016 Academic Article GET IT
PO-43 - Differential coagulation factor expression in neuroendocrine prostate cancer (PC), metastatic castrate-resistant PC, and localized prostatic adenocarcinoma. Thrombosis research. 2016 Academic Article GET IT
Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 66
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nature medicine. 2016 Academic Article GET IT
Times cited: 933
Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer. European urology. 2016 Academic Article GET IT
Times cited: 17
Prostate-Specific Membrane Antigen Is a Potential Antiangiogenic Target in Adrenocortical Carcinoma. The Journal of clinical endocrinology and metabolism. 2016 Academic Article GET IT
Times cited: 14
Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody. Current radiopharmaceuticals. 2016 Review GET IT
Times cited: 54
The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 101
Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma. Clinical genitourinary cancer. 2015 Academic Article GET IT
Times cited: 70
Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy. Critical reviews in oncology/hematology. 2015 Review GET IT
Times cited: 37
Integrative Clinical Genomics of Advanced Prostate Cancer. Cell. 2015 Article GET IT
Times cited: 340
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 148
Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. JAMA oncology. 2015 Academic Article GET IT
Times cited: 216
Integrative clinical genomics of advanced prostate cancer. Cell. 2015 Academic Article GET IT
Times cited: 2094
The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer. Current treatment options in oncology. 2015 Review GET IT
Times cited: 3
Novel molecular targets for urothelial carcinoma. Expert opinion on therapeutic targets. 2015 Review GET IT
Times cited: 8
Microtubule inhibitor-based antibody-drug conjugates for cancer therapy. OncoTargets and therapy. 2014 Review GET IT
Times cited: 53
ERG induces taxane resistance in castration-resistant prostate cancer. Nature communications. 2014 Academic Article GET IT
Times cited: 91
99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2014 Academic Article GET IT
Times cited: 109
Neuroendocrine prostate cancer after hormonal therapy: knowing is half the battle. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Comment GET IT
Times cited: 25
Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential. Molecular diagnosis & therapy. 2014 Academic Article GET IT
Times cited: 39
Predictors of survival in patients with disease recurrence after radical nephroureterectomy. BJU international. 2014 Academic Article GET IT
Times cited: 21
Immunologics and chemotherapeutics for renal cell carcinoma. Seminars in interventional radiology. 2014 Review GET IT
Times cited: 9
Exploring the role of anti-angiogenic therapies in prostate cancer: results from the phase 3 trial of sunitinib. Asian journal of andrology. 2014 Comment GET IT
Times cited: 1
Circulating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flow. PloS one. 2013 Academic Article GET IT
Times cited: 34
An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Cancer. 2013 Academic Article GET IT
Times cited: 74
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer. 2013 Academic Article GET IT
Times cited: 90
The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy. World journal of urology. 2013 Academic Article GET IT
Times cited: 31
Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancer. Frontiers in oncology. 2013 Academic Article GET IT
Times cited: 21
Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC). Cancer chemotherapy and pharmacology. 2013 Academic Article GET IT
Times cited: 16
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 321
PSMA-targeted dendrimers: a patent evaluation (WO2012078534). Expert opinion on therapeutic patents. 2013 Academic Article GET IT
Times cited: 1
2-weekly versus 3-weekly docetaxel for prostate cancer. The Lancet. Oncology. 2013 Comment GET IT
Times cited: 2
Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia (New York, N.Y.). 2013 Academic Article GET IT
Times cited: 190
Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling. British journal of cancer. 2012 Academic Article GET IT
Times cited: 28
Challenges in recognizing treatment-related neuroendocrine prostate cancer. 2012 GET IT
Times cited: 163
Isolation and characterization of circulating tumor cells in prostate cancer. Frontiers in oncology. 2012 Academic Article GET IT
Times cited: 72
Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. European urology. 2012 Academic Article GET IT
Times cited: 328
Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. BJU international. 2012 Academic Article GET IT
Times cited: 73
Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. BJU international. 2012 Academic Article GET IT
Times cited: 62
Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?. World journal of urology. 2012 Academic Article GET IT
Times cited: 14
A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer. Investigational new drugs. 2012 Academic Article GET IT
Times cited: 55
Extranodal extension is a powerful prognostic factor in bladder cancer patients with lymph node metastasis. European urology. 2012 Academic Article GET IT
Times cited: 51
Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy. BJU international. 2012 Academic Article GET IT
Times cited: 25
Accurate preoperative prediction of non-organ-confined bladder urothelial carcinoma at cystectomy. BJU international. 2012 Academic Article GET IT
Times cited: 41
Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomy. European urology. 2012 Academic Article GET IT
Times cited: 42
Is adjunctive systemic chemotherapy after cystectomy for T2N+ disease of therapeutic benefit?. The Journal of urology. 2012 Academic Article GET IT
Times cited: 3
Prostate-specific membrane antigen-based imaging. Urologic oncology. 2012 Review GET IT
Times cited: 84
Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy. Advances in urology. 2012 Academic Article GET IT
Times cited: 38
Editorial comment. The Journal of urology. 2012 Editorial Article GET IT
Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. PloS one. 2012 Academic Article GET IT
Times cited: 181
The current role of androgen deprivation in patients undergoing dose-escalated external beam radiation therapy for clinically localized prostate cancer. Prostate cancer. 2012 Academic Article GET IT
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer discovery. 2011 Academic Article GET IT
Times cited: 633
Novel therapeutics for the management of castration-resistant prostate cancer (CRPC). BJU international. 2011 Review GET IT
Times cited: 22
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981. American journal of clinical oncology. 2011 Academic Article GET IT
Times cited: 9
Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer. Asian journal of andrology. 2011 Academic Article GET IT
Times cited: 1
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer research. 2011 Academic Article GET IT
Times cited: 356
Prostate-specific membrane antigen-based therapeutics. Advances in urology. 2011 Academic Article GET IT
Times cited: 65
New therapies for castration-resistant prostate cancer: efficacy and safety. European urology. 2011 Review GET IT
Times cited: 123
Boning up on prognostic factors in advanced renal cell carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Editorial Article GET IT
Times cited: 1
PET/CT Imaging and Radioimmunotherapy of Prostate Cancer. Seminars in nuclear medicine. 2011 Review GET IT
Times cited: 75
A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU international. 2010 Academic Article GET IT
Times cited: 67
Editorial comment. The Journal of urology. 2010 Editorial Article GET IT
Times cited: 1
Primary squamous cell carcinoma of the urinary bladder presenting as peritoneal carcinomatosis. 2010 GET IT
Times cited: 6
Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer. Urologic oncology. 2010 Academic Article GET IT
Times cited: 13
Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer. 2010 Academic Article GET IT
Times cited: 122
Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab on a chip. 2009 Academic Article GET IT
Times cited: 317
Editorial comment. The Journal of urology. 2009 Editorial Article GET IT
Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomy. BJU international. 2008 Academic Article GET IT
Times cited: 10
Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with Stage IV melanoma. Cancer. 2006 Academic Article GET IT
Times cited: 42
Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC). Investigational new drugs. 2004 Academic Article GET IT
Times cited: 9
Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma. Cancer. 2003 Academic Article GET IT
Times cited: 112

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Heating cold prostate tumors with PSMA-targeted alpha therapy and pembrolizumab awarded by United States Department of Defense Principal Investigator 2020 - 2024
Targeted Therapies awarded by United States Department of Defense Principal Investigator 2022 - 2023

Clonal Hematopoiesis as a determinant for bone marrow toxicities for targeted radiation therapies in prostate cancer. awarded by United States Department of Defense Co-Investigator 2022 - 2025
The Development of Radiolabeled Positional isomers of [11C]Pyruvate for Imaging Cancer Metabolism awarded by National Institute of Biomedical Imaging & Bioengineering Co-Investigator 2020 - 2024
Transferrin Receptor Identifies a Comprehensive pool of Circulating Tumor Cells with unique molecular features from metastatic Prostate Cancer Patients awarded by United States Department of Defense Co-Investigator 2019 - 2023

Weill Cornell Medicine (WCM) SPORE in Prostate Cancer awarded by National Cancer Institute Key Personnel 2017 - 2023

Measuring Patient-Reported Outcomes Related to Radiopharmaceuticals for Prostate Cancer awarded by United States Department of Defense Principal Investigator Subaward 2020 - 2023
Therapeutic Targeting of AR Variant Prostate Cancer with a Novel Antibody Drug Conjugate awarded by American Society of Transplatation Principal Investigator Subaward 2017 - 2023

more ...

less ...

Background

education and training

M.S., Weill Cornell Graduate School of Medical Sciences 2010
M.D., University of Southern California, Keck School of Medicine 1998
B.S., Georgetown University 1993

Contact

full name

Scott T. Tagawa

primary email

stt2007@med.cornell.edu

webpage

Clinical Profile

VIVO Weill Cornell Medical College

Scott T. Tagawa Professor of Medicine

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

webpage